Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer — RESTRICT  

Kidney Cancer Clinical Trial

Official title: Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

Status Active, not recruiting

Clinical Trial Summary

The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

Clinical Trial Description

The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT) is a randomized study to investigate blood sparing using autologous normovolemic hemodilution (ANH) or cell salvage at the time of nephrectomy for locally advanced kidney cancer after assessing inclusion criteria patients will be randomized to undergo standard blood management including the possibility of allogenic transfusion vs autologous blood transfusion. There are multiple ways patients can receive allogenic or autologous blood, including veno-venous bypass or cardiopulmonary bypass (typically reserved for patients with a thrombus above the level of the hepatic veins or entering the heart). ;

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms

• NCT number: NCT04922307
• Study type: Interventional
• Source: Vanderbilt University Medical Center
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 23, 2021
• Completion date: June 15, 2027